Afnet Redakteur

Heart Seminar of the AF-B-STEP Project and the Heart Center of the University of Cologne

by

nter dem Motto „Risikofaktoren vermeiden – Lebensqualität erhöhen“ touren die roten Infobusse die Aufklärungsinitiative „Herzenssache Lebenszeit“ quer durch Deutschland. In bis zu 100 Städten beraten Experten von regionalen Partnern wie Diabetologen, Kardiologen und Neurologen sowie Vertreter von Selbsthilfegruppen oder Krankenkassen die Besucher kostenlos. Mithilfe von Testbögen sowie Blutdruck-, Blutzucker- und Cholesterinmessungen erhält jeder auf Wunsch Auskunft über seinen Gesundheitszustand und sein persönliches Risiko hinsichtlich Diabetes und kardiovaskulärer Erkrankungen. Zudem gibt es umfangreiches, kostenfreies Informationsmaterial und die Möglichkeit, sich über offene Fragen auszutauschen.

AFNET at the 2026 ESC Congress in Munich

by

The 2026 ESC Congress took place in Munich from 28th to 31st of August 2026. The annual congress of the European Society of Cardiology (ESC) is one of the world’s leading professional events in cardiology. It brings together experts from academia, research and clinical practice from around the globe.

Steering Committee Retreat 2026

by

Shaping the future together: As part of this year’s steering committee retreat, committee members will convene in Muenster for two days (from June 29th -30th) to discuss strategic issues, generate new ideas and prepare the next steps in the development of the association.

Herzenssache Lebenszeit

by

The public awareness campaign “Herzenssache Lebenszeit” made a successful stop at Paderborn’s Town Hall Square. Together with partners, AFNET employees provided information on heart health, atrial fibrillation and prevention. Many visitors took advantage of the free health screenings and the opportunity to speak with experts in person.

AI-driven analysis of atrial fibrillation burden in pacemaker patients reveals no effect of AF burden on stroke

by

An analysis of the NOAH – AFNET 6 trial used large language models to extract AF burden from pacemaker data in patients with device-detected atrial fibrillation. This approach enables to evaluate the impact of AF burden on cardiovascular outcome and on the effectiveness and safety of anticoagulation in pacemaker patients. The AF burden in the population was 0.4%, with 20% of patients showing a baseline AF burden of more than 1%. In these patients, there was no effect of AF burden on stroke or other cardiovascular events. Today, the findings were presented by AFNET board member Prof. Ulrich Schotten, Maastricht, as a hotline at the Heart Rhythm congress 2026 in Chicago (1).